Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03225040 · ClinicalTrials.gov registry record
Bone MicroArchitecture in Acromegaly
A clinical trial of Acromegaly and Osteoporosis Risk, sponsored by Columbia University.
- Completed
- Registry status
- 77
- Enrollment target
- 1
- Study location
NCT03225040 is a study of Acromegaly and Osteoporosis Risk that has completed, run by Columbia University. The registered enrollment target is 77 participants, below the 95-participant average among 13 other Acromegaly trials with a reported enrollment target (19% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03225040, a study of Acromegaly and Osteoporosis Risk, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 77 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators will conduct a cross-sectional study of bone density, bone microarchitecture, vertebral fractures and trabecular bone score in 25 patients with acromegaly treated with Pegvisomant, the growth hormone (GH) receptor antagonist for at least 1 year and with normal insulin-like growth factor-1 (IGF-1) levels. This study aims to describe the bone architecture and associated biochemical indices of bone turnover and metabolism in patients with active acromegaly and how these are altered with treatment of the disease.
Conditions Studied
Interventions
- DRUG Pegvisomant
Study Locations (1)
New York
- Neuroendocrine Unit and Pituitary Center, Columbia University - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 77 participants |
| Start Date | 2016-08-03 |
| Est. Completion | 2019-12-21 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03225040
The ClinicalTrials.gov registry entry for NCT03225040 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 77 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 95-participant average among 13 other Acromegaly trials with a reported enrollment target (19% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Acromegaly appearing as the primary indexed condition, and to 1 intervention - of which Pegvisomant is the first listed.
NCT03225040 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03225040 about?
NCT03225040 is a clinical study titled "Bone MicroArchitecture in Acromegaly". The investigators will conduct a cross-sectional study of bone density, bone microarchitecture, vertebral fractures and trabecular bone score in 25 patients with acromegaly treated with Pegvisomant, the growth hormone (GH) receptor antagonist for at least 1 year and with normal insulin-like growth f...
What is the current status of trial NCT03225040?
This trial is currently completed. The enrollment target is 77 participants. The study started on 2016-08-03. Estimated completion is 2019-12-21.
What conditions does trial NCT03225040 study?
This clinical trial studies the following conditions: Acromegaly, Osteoporosis Risk.
What interventions are being tested in trial NCT03225040?
The interventions under investigation include: Pegvisomant (DRUG).
Who is sponsoring clinical trial NCT03225040?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03225040 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acromegaly
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs
RECRUITING · Phase 3
-
Diet in the Management of Acromegaly
RECRUITING · NA
-
Study of MAR002 in Healthy Men
RECRUITING · Phase 1
-
Peri-operative Dynamics of the Growth Hormone Axis in Subjects With Acromegaly
ACTIVE NOT RECRUITING
-
A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (PATHFNDR-2)
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.